Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway

Brain

Volumn 129, Issue 8, 2006, Pages 1984-1992

  Miyamoto, Katsuichi ^a,b   Miyake, Sachiko ^a   Mizuno, Miho ^a   Oka, Nobuyuki ^c   Kusunoki, Susumu ^b   Yamamura, Takashi ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c National Hospital Organization Minami Kyoto Hospital   (Japan)

Author keywords

Celecoxib; COX 2 inhibitor; Experimental autoimmune encephalomyelitis; Multiple sclerosis

Indexed keywords

CELECOXIB; CELL ADHESION MOLECULE; CHEMOKINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INDOMETACIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NIMESULIDE; PADGEM PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; INFLAMMATORY CELL; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 33747894116     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl170     Document Type: Article

References (33)

1. Alloza I, Baxter A, Chen Q, Matthiesen R, Vanderbroeck K. Celecoxib inhibits interleukin-12 αβ and β2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. Mol Pharm 2006; 69: 1579-87.
2. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277: 27613-21.
3. Cuzzocrea S, Mazzon E, Serraino I, Dugo L, Centorrino T, Ciccolo A, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol 2001; 431: 91-102.
4. Cuzzocrea S, Mazzon E, Sautebin L, Dugo L, Serraino I, De Sarro A, et al. Protective effects of celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat. Biochem Pharmacol 2002; 63: 785-95.
5. Deininger MH, Schluesener HJ. Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma. J Neuroimmunol 1999; 95: 202-8.
6. Dietrich JB. The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J Neuroimmunol 2002; 128: 58-68.
7. Engelhardt B, Vestweber D, Hallmann R, Schulz M. E- and P-selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood 1997; 90: 4459-72.
8. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742-4.
9. Hofmann N, Lachnit N, Streppel M, Witter B, Neiss WF, Guntinas-Lichius O, et al. Increased expression of ICAM-1, VCAM-1, MCP-1, and MIP-1 alpha by spinal perivascular macrophages during experimental allergic encephalomyelitis in rats. BMC Immunol 2002; 6: 11.
10. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397-403.
11. Krakowski ML, Owens T. The central nervous system environment controls effector CD4+ T cell cytokine profile in experimental allergic encephalomyelitis. Eur J Immunol 1997; 27: 2840-7.
12. Kumar V, Aziz F, Sercarz E, Miller A. Regulatory T cells specific for the same framework 3 region of the Vb8.2 chain are involved in the control of collagen II-induced arthritis and experimental autoimmune encephalomyelitis. J Exp Med 1997; 185: 1725-33.
13. Kusunoki N, Yamazaki R, Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum 2002; 46: 3159-67.
14. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004; 96: 1769-80.
15. Meyer F, Ramanujam KS, Gobert AP, James SP, Wilson KT. Cutting edge: cyclooxygenase-2 activation suppresses Th1 polarization in response to Helicobacter pylori. J Immunol 2003; 171: 3913-7.
16. Miyamoto K, Oka N, Kawasaki T, Satoi H, Akiguchi I, Kimura J. The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis. Neuroreport 1998; 9: 2331-4.
17. Miyamoto K, Oka N, Kawasaki T, Satoi H, Matsuo A, Akiguchi I. The action mechanism of cyclooxygenase-2 inhibitor for treatment of experimental allergic neuritis. Muscle Nerve 1999; 22: 1704-9.
18. Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, Akiguchi I. New cyclooxygenase-2 inhibitor for treatment of experimental autoimmune neuritis. Muscle Nerve 2002; 25: 280-2.
19. Muthian G, Raikwar HP, Johnson C, Rajasingh J, Kalgutkar A, Marnett LJ, et al. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol 2006; 26: 73-85.
20. Nakatsuji S, Terada N, Yoshimura T, Horie Y, Furukawa M. Effects of nimesulide, a preferential cyclooxygenase-2 inhibitor, on carrageenan-induced pleurisy and stress-induced gastric lesions in rats. Prostaglandins 1996; 55: 395-402.
21. Nicholson LB, Kuchroo VK. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr Opin Immunol 1996; 8: 837-42.
22. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzene sulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347-65.
23. Prosiegel M, Neu I, Mallinger J, Wildfeuer A, Mehlber L, Vogl S, et al. Suppression of experimental autoimmune encephalomyelitis by dual cyclooxygenase and 5-lipoxygenase inhibition. Acta Neurol Scand 1989; 79: 223-6.
24. Scott GS, Kean RB, Fabis MJ, Mikheeva T, Brimer CM, Phares TW, et al. ICAM-1 upregulation in the spinal cords of PLSJL mice with experimental allergic encephalomyelitis is dependent upon TNF-alpha production triggered by the loss of blood-brain barrier integrity. J Neuroimmunol 2004; 155: 32-42.
25. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004; 173: 2011-22..
26. Simmons RD, Hugh AR, Willenborg DO, Cowden WB. Suppression of active but not passive autoimmune encephalomyelitis by dual cyclo-oxygenase and 5-lipoxygenase inhibition. Acta Neurol Scand 1992; 85: 197-9.
27. Snijdewint F, Kalinski P, Wierenga E, Bos J, Kapasenberg M. Prostaglandin E2 differentially modulate cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993; 150: 5321.
28. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, et al. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046-50.
29. Wang K, Tarakji K, Zhou Z, Zhang M, Forudi F, Zhou X, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 2005; 45: 61-7.
30. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
31. Weber F, Meyermann R, Hempel K. Experimental allergic encephalomyelitis-prophylactic and therapeutic treatment with the cyclooxygenase inhibitor piroxicam (Feldene). Int Arch Allergy Appl Immunol 1991; 95: 136-41.
32. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6.
33. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997; 186: 1677-87.